CorMedix Inc. filed a current report on November 9, 2026, disclosing an Asset Purchase Agreement signed November 8, 2026, under which the company agreed to acquire substantially all assets of Heron Therapeutics, Inc. for a combination of cash, stock, royalties, and contingent earn-out payments.

Key Highlights

  • Cash consideration: CorMedix agreed to pay Heron Therapeutics $145.0 million in cash, subject to certain adjustments for closing cash and net working capital, with $2.0 million deposited into escrow with Citibank, N.A. at closing.
  • Stock consideration: CorMedix agreed to issue 14,583,333 shares of its common stock (par value $0.001 per share) to Heron Therapeutics as part of the purchase price.
  • Royalties: CorMedix agreed to pay royalties equal to 5.0% of the amount by which aggregate annual net sales of CINVANTI, SUSTOL, and certain other covered products exceed $25.0 million in each of calendar years 2027, 2028, and 2029, if and when payable.
  • Earn-out payments: CorMedix agreed to pay $25.0 million if net sales of ZYNRELEF for calendar year 2028 equal or exceed $65.0 million, and an additional $30.0 million if such net sales equal or exceed $95.0 million, payable in cash, stock, or a combination, if and when payable.
  • Board approval: The CorMedix board of directors unanimously approved the Purchase Agreement, the Asset Sale, and other related transactions, and agreed to recommend them to stockholders.
  • No financing condition: According to the filing, the company's obligation to consummate the Asset Sale "is not subject to any financing conditions."
  • Termination fee: Heron Therapeutics may terminate the agreement to accept a superior proposal only if it pays a $4.0 million termination fee, among other conditions.

CorMedix and Heron Therapeutics: Terms of the November 8 Asset Purchase Agreement

According to the filing, CorMedix Inc. (NASDAQ:CRMD) and Heron Therapeutics, Inc. entered into the Asset Purchase Agreement on November 8, 2026. Under that agreement, Heron agreed to sell substantially all of its assets to CorMedix, excluding certain specified assets, while CorMedix agreed to acquire those assets and assume certain of Heron's liabilities. The transaction is structured as a multi-part consideration package combining upfront cash and stock payments with contingent royalties and earn-outs tied to future product sales.

The filing states that post-closing adjustments to the $145.0 million cash consideration may not exceed $10.0 million in either direction. For the earn-out payments tied to ZYNRELEF net sales in 2028, any portion of earn-out paid in shares that would cause total shares issued under the agreement to exceed 19.9% of common stock outstanding at closing would instead be paid in cash, according to the filing. The Purchase Agreement also includes a five-year non-compete covenant binding Heron following closing, covering businesses involving treatment of chemotherapy-induced or post-operative nausea and vomiting with injectable products containing aprepitant or granisetron, or treatment of post-operative pain with certain non-opioid anesthetics. A three-year mutual non-solicitation of employees covenant is also included, the filing disclosed.

The filing notes that closing conditions include expiration or termination of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, approval for listing on the Nasdaq Global Market of the shares to be issued as stock consideration, and approval by holders of a majority of Heron's issued and outstanding shares entitled to vote. The filing specifies that no vote of CorMedix stockholders is required in connection with the Asset Sale or the issuance of stock consideration. The representations and warranties of the parties do not survive the closing, except in cases of fraud, according to the filing.

What Was Disclosed

CorMedix disclosed an Asset Purchase Agreement with Heron Therapeutics dated November 8, 2026, covering the acquisition of substantially all Heron assets for $145.0 million in cash, 14,583,333 shares of CorMedix common stock, product royalties, and contingent earn-out payments tied to ZYNRELEF sales.